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I–IV, also known as the L1, S1, L2, and S2 domains,
respectively (Bajaj et al., 1987). Domains I and III share
37% amino acid identity, while domains II and IV are
homologous Cys-rich domains, CR1 and CR2, respec-
tively (Ward et al., 1995). A truncated form of EGFR is the
Hideo Ogiso,1,2 Ryuichiro Ishitani,1,3
Osamu Nureki,1,3,4 Shuya Fukai,1,3,4
Mari Yamanaka,2 Jae-Hoon Kim,2 Kazuki Saito,1,2
Ayako Sakamoto,1 Mio Inoue,1 Mikako Shirouzu,1,4
and Shigeyuki Yokoyama1,2,3,4,5
product of the erbB oncogene of avian erythroblastosis1RIKEN Genomic Sciences Center
virus (Yamamoto et al., 1983; Downward et al., 1984).1-7-22 Suehiro-cho
EGF binding to the extracellular region of EGFR in-Tsurumi, Yokohama, Kanagawa 230-0045
duces receptor dimerization, which is supposed to bringJapan
the two cytoplasmic tyrosine kinase domains of the re-2 Yokoyama CytoLogic Project
ceptors close enough for autophosphorylation and toERATO, Japan Science and Technology
thereby activate the intrinsic tyrosine kinase activity.Corporation
The EGF receptor tyrosine kinase triggers numerousJapan
downstream signaling pathways, like other receptor3 Department of Biophysics and Biochemistry
tyrosine kinases and tyrosine kinase-linked cytokine re-Graduate School of Science
ceptors (Carpenter and Cohen, 1990; Ullrich and Schles-The University of Tokyo
singer, 1990). On the other hand, spontaneous oligomer-7-3-1 Hongo
ization accompanied by tyrosine phosphorylation hasBunkyo-ku, Tokyo 113-0033
been reported for oncogenic mutants lacking either partJapan
or most of the extracellular region (Haley et al., 1989;4 Cellular Signaling Laboratory and Structurome
Huang et al., 1997). Thus, the extracellular region is alsoGroup
likely to be crucial in the suppression of the ligand-RIKEN Harima Institute at SPring-8
independent, spontaneous oligomerization.1-1-1 Kohto
Two EGF molecules form a complex with two EGFRMikazuki-cho, Sayo, Hyogo 679-5148
molecules (Brown et al., 1994; Lemmon et al., 1997;Japan
Odaka et al., 1997; Domagala et al., 2000). Three possi-
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ization have been proposed. The first possibility is thatSummary
the receptor dimerization is mediated primarily by the
interaction between two EGF molecules. In this context,Epidermal growth factor (EGF) regulates cell prolifera-
it has been reported that two EGFs form a dimer in thetion and differentiation by binding to the EGF receptor
crystal structure (Lu et al., 2001). Actually, a dimer of(EGFR) extracellular region, comprising domains I–IV,
nerve growth factor (NGF) induces receptor dimerizationwith the resultant dimerization of the receptor tyrosine
by this “ligand dimerization” mechanism (Wiesmann etkinase. In this study, the crystal structure of a 2:2
al., 1999). The second possibility is that the receptorcomplex of human EGF and the EGFR extracellular
dimerization is mediated primarily by the “bivalency” ofregion has been determined at 3.3 A˚ resolution. EGFR
the ligand to the receptor, i.e., the simultaneous interac-domains I–III are arranged in a C shape, and EGF is
tions of each ligand with two receptor molecules (Lem-docked between domains I and III. The 1:1 EGF•EGFR
mon et al., 1997), as in the case of granulocyte colony-complex dimerizes through a direct receptor•receptor
stimulating factor (GCSF) (Aritomi et al., 1999). For theinteraction, in which a protruding -hairpin arm of
ternary complexes of fibroblast growth factor (FGF), the
each domain II holds the body of the other. The unique
FGF receptor (FGFR), and heparin, two distinct “ligand-
“receptor-mediated dimerization” was verified by mediated” receptor dimerization mechanisms, a hepa-
EGFR mutagenesis. rin-promoted “ligand bivalency” mechanism (Plotnikov
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Introduction et al., 2000), and a unique “heparin-mediated ligand
dimerization” mechanism (Pellegrini et al., 2000) have
Epidermal growth factor (EGF), a growth factor that was been reported. In contrast to these ligand-mediated re-
first isolated from the submaxillary glands of the adult ceptor dimerization mechanisms, the third possibility is
male mouse, stimulates the proliferation of a number of a “receptor-mediated” mechanism, in which EGF bind-
epithelial tissues both in vivo and in vitro (Carpenter and ing induces conformational changes of EGFR so as to
Cohen, 1979). Human EGF is a single-chain polypeptide expose its dimerization surface (Lemmon et al., 1997).
consisting of 53 amino acid residues, including six Cys However, no growth factor that forms a 2:2 complex has
residues that form three disulfide bonds. The human been shown to induce the receptor-mediated dimer-
EGF receptor (EGFR) is a 1186 amino acid transmem- ization.
brane glycoprotein (Ullrich et al., 1984). EGF binding by Another member of the EGF family, transforming
EGFR occurs within the amino-terminal 622 amino acid growth factor- (TGF-), is structurally related, and ex-
extracellular region, which is divided into four domains, erts its action by binding to EGFR (Derynck et al., 1984;
Marquardt et al., 1984). Three homologs of EGFR, or
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and ErbB-4 (Olayioye et al., 2000). The EGFR family mental phases enough for model building (Figure 2B).
The final model was refined to 3.3 A˚ resolution with ancomprises the four members from mammals and one
each from Drosophila melanogaster and Caenorhabditis R factor of 25.5% (Rfree  32.6%) (Table 1). The crystal
structure contains one 2:2 EGF•EGFR complex perelegans. EGF and TGF- bind directly only to EGFR,
while neuregulins (also known as heregulins or neu dif- asymmetric unit (Figure 2). The N-terminal residue, resi-
dues 158–162 (the C-terminal region of domain I), 169–ferentiation factors) are specific to ErbB-3 and ErbB-4.
Although ErbB-2 is a highly active tyrosine kinase, cells 170 (the N-terminal region of domain II), 179–180, 302–
308 (the C-terminal region of domain II), and 513–619expressing ErbB-2 alone, with no other member of the
EGFR family, failed to bind any ligands. Therefore, in (most of domain IV) of one receptor molecule and the
N-terminal two residues, residues 158–160, 179, 305–addition to homodimerization, these specific ligands
also induce heterooligomerization of different pairs of 309, and 513–619 of the other receptor molecule are
structurally disordered. In the ligand molecules, resi-the EGFR family members (Tzahar et al., 1996; Graus-
Porta et al., 1997). dues 1–4 and 50–53 are disordered.
Many site-directed mutagenesis studies of the ligand
showed that several amino acid residues of EGF, such Structure of the 2:2 Complex of EGF and EGFR
as Tyr13, Ile23, Arg41, and Leu47, are crucial for binding In the 2:2 EGF•EGFR complex (Figure 1), each EGF mol-
to the EGFR (Engler et al., 1992; Koide et al., 1992b; ecule is bound to only one of the two EGFR molecules,
Tadaki and Niyogi, 1993). Domains I (L1) and III (L2) of or in other words, two 1:1 EGF•EGFR complexes are
the receptor have been shown to play minor and major dimerized. The 2:2 complex is well separable from the
roles, respectively, in the EGF/TGF- binding, by ligand other complexes in the crystal lattice (Figures 2C and
binding analyses of EGFR chimeras (Lax et al., 1989; 2D). The structures of the two 1:1 EGF•EGFR complexes
Kim et al., 2002), and limited fragments of human EGFR (1:1 complexes A and B) in the asymmetric unit are quite
(Kohda et al., 1993; Elleman et al., 2001), by crosslinking similar to each other, with root-mean-square deviations
analyses of mouse EGF and human EGFR (Wu et al., (rmsd) of 0.29 A˚ and 0.76 A˚ for the C atoms of residues
1990; Woltjer et al., 1992; Summerfield et al., 1996) and 5–49 of EGF and residues 6–512 of EGFR, respectively.
by an antibody competition analysis (Wu et al., 1989). In each 1:1 complex, domains I, II, and III of EGFR are
The first three domains, I (L1), II (S1/CR1), and III (L2), arranged in a C shape, and the EGF is accommodated
of EGFR exhibit about 25% sequence identities with the between domains I and III (Figure 1). This is consistent
first three domains (L1, Cys-rich, and L2) of the type-1 with the previous biochemical results that domains I and
insulin-like growth factor receptor (IGF-1R). The crystal III are involved in the EGF binding (Lax et al., 1989; Wu
structure of an IGF-1R fragment consisting of the first et al., 1989, 1990; Woltjer et al., 1992; Kohda et al., 1993;
three domains has been determined in the absence of Summerfield et al., 1996; Elleman et al., 2001; Kim et al.,
ligand (Garrett et al., 1998), while crystals of the EGFR 2002). The ligand•receptor interface on each receptor
extracellular fragment have been obtained (Gunther et consists of three sites, which are designated hereafter
al., 1990; Degenhardt et al., 1998). as site 1 in domain I and sites 2 and 3 in domain III
In the present study, the crystal structure of a 2:2 (Figure 3A). In the 2:2 complex, the two EGF ligands are
complex of human EGF and EGFR was determined at located 79 A˚ apart, on the opposite sides of the receptor
3.3 A˚. The structure confirms many experimental results dimer. This is consistent with the previous suggestion,
reported thus far, such as the residues of EGF involved based on the low probability of fluorescence-resonance
in the receptor binding, and further identifies three EGF energy transfer using fluorescent dye-labeled EGF, that
binding sites on domains I and III of the receptor. More- the distance between the two EGF molecules in the
over, the dimeric EGF•EGFR structure demonstrates dimeric EGF•EGFR complex was longer than 58 A˚ (Sako
receptor-mediated dimerization, in which the two EGFR et al., 2000). Remarkably, in the center of the 2:2 com-
molecules are directly bound to each other by interac- plex, the two receptor molecules are bound with each
tions between each domain II. The same dimerization other through direct interactions between each domain
mode was found for an independently determined struc- II. Therefore, the mechanism of the EGFR dimerization
ture of the 2:2 complex of TGF- and EGFR (Garrett et is receptor-mediated. The receptor-mediated dimeriza-
al., 2002). tion has also been seen in the TGF-•EGFR complex
structure (Garrett et al., 2002 [this issue of Cell]). The
details of the EGF•EGFR and EGFR•EGFR interactionsResults and Discussion
are described below.
The structure of the EGF molecule in the present com-Structure Determination
An extracellular fragment consisting of domains I–IV of plex (Figure 3B) is very similar to the crystal structures
of human EGF itself (molecules A and B) (Lu et al., 2001),human EGFR (residues 1–619, Mr of 95 kDa) was ex-
pressed by Chinese hamster ovary Lec8 cells, purified, with rmsd values of 1.6–2.9 A˚ for the corresponding C
atoms. The primary structure of EGF is divided into thedeglycosylated, and crystallized with human EGF (Mr of
6.2 kDa). The crystal structure was determined at 3.3 A˚ A, B, and C loops by the disulfide bonds Cys6–Cys20,
Cys14–Cys31, and Cys33–Cys42 (Figure 3B). The A loopresolution (Figures 1 and 2). First, the protein phases
were determined by the multiwavelength anomalous (residues 6–19) contains some -helical structure, the
B loop (residues 20–31) forms a two-stranded antiparal-dispersion (MAD) method, using selenomethionine-
labeled EGFR (Figure 2A). Density modification by sol- lel  sheet, and the C loop (residues 33–42) is a part of
the second antiparallel  sheet. While Asn32, locatedvent flattening, histogram matching, and 2-fold noncrys-
tallographic symmetry averaging improved the experi- between two Cys residues, may function as a hinge
Crystal Structure of EGF:EGF Receptor Complex
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Figure 1. Crystal Structure of the 2:2 EGF-EGFR Complexes
(A) Ribbon diagram with the approximate two-fold axis oriented vertically. One EGF chain in the 2:2 EGF•EGFR complex is pale green, and
the other EGF chain is pink. Domains I, II, III, and IV in one receptor in the dimer are colored yellow, orange, red, and gray, respectively.
Domains I, II, III, and IV in the other receptor are colored cyan, dark blue, pale blue, and gray, respectively. Most of domain IV is disordered.
The disulfide bonds are shown in yellow. The intervening parts that were not assigned are transparent.
(B) The top view of (A).
(C) A surface model corresponding to (A).
between the two globules constituting EGF (Groenen of the unliganded IGF-1R structure (Garrett et al., 1998),
except for some points described below. The rmsd foret al., 1994), the relative orientation between the two
globules in the present receptor bound structure is es- the corresponding C atoms between the second do-
mains of EGFR and IGF-1R is 3.2 A˚. In the present struc-sentially the same as that in the solution structure
(Kohda and Inagaki, 1992). ture of the EGF bound EGFR, most of domain IV, which
connects the transmembrane and cytoplasmic regions,The receptor structure is consistent with the previous
study on the disulfide bond topology of EGFR (Abe et is disordered; the two equivalent C-terminal residues
(Val481) of domain III of EGFR are located 77 A˚ apart.al., 1998). Domains I (L1) and III (L2) fold into “single-
stranded right-handed -helical barrels,” whose back-
bone structures are individually similar to those of the Ligand•Receptor Interactions
The site 1, 2, and 3 interfaces between the ligand andcorresponding domains of the unliganded IGF-1R (Gar-
rett et al., 1998), with rmsd values (for the corresponding the receptor are extensive, with totally buried surfaces
of about 720 and 730 A˚2 for domains I and III, respectivelyC atoms) of 2.1 and 4.0 A˚ for domains I and III, respec-
tively. Residues 10–17, 85–94, and 101–107 in domain I (Figure 3A). The B loop (residues 20–31) of EGF interacts
with site 1 in domain I (Figure 3C), the region containingand residues 316–325, 353–362, and 404–413 in domain
III loop out from the right-handed -helical barrels. Do- the A loop (residues 6–19) and Arg41 of EGF interacts
with site 2 in domain III (Figure 3D), and the C-terminalmain II has a similar fold to that of the second domain
Cell
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Figure 2. Experimental Electron Density Maps and Crystal Packing of the Human EGF•EGFR Complex
EGF and the EGFR domains are colored in the same manner as in Figure 1.
(A) Anomalous Fourier map (contoured at 4.5) calculated from the selenomethionine data sets, with the backbones of the 2:2 EGF•EGFR
complex. The peaks corresponding to 11 out of the 13 Se atoms used for the phase calculation were intensely visible.
(B) Experimental density at 3.5 A˚ resolution from the selenomethionine data set, contoured at 1.5.
(C) Crystal packing of the 2:2 EGF•EGFR complex in the unit cell.
(D) Crystallographic contact between the two 2:2 EGF•EGFR complexes. The three-fold screw axis is indicated.
region around Arg45 interacts with site 3 in domain III the receptor binding activity of EGF, but its replacement
by His, which may mimic Asn with respect to the hydro-(Figure 3E).
In site 1, the side chains of Leu14, Tyr45, Leu69, and gen donor activity, did not (Koide et al., 1992a). The
Glu90 side chain of EGFR is close to the Lys28 sideLeu98 in domain I of EGFR hydrophobically interact with
Met21, Ile23, and Leu26 in the B loop of EGF (Figures chain of EGF (Figure 3C), whereas the mutation of Lys28
to Leu had only a negligible effect on the receptor bind-3B and 3C). The involvement of these hydrophobic resi-
dues of EGF in the receptor binding is consistent with ing activity (Campion et al., 1990).
In site 2, the Val350 and Phe357 side chains in domainthe previous site-directed mutagenesis studies on EGF.
Replacements of Ile23 with Ala, Val, Leu, Phe, Trp, and III of EGFR hydrophobically interact with Leu15 and
Tyr13, respectively, of EGF. Correspondingly, the re-so on, have shown that Ile23 of EGF is requisite for tight
binding with the receptor, where the Ile residue is of the placement of Tyr13 with Phe did not reduce the receptor
binding activity, but those with Val, Ile, Ala, Arg, and sooptimum size (Koide et al., 1992b). Actually, the Ile23
binding site, formed by the side chains of Leu14, Tyr45, on reduced it depending on the shape and the hydro-
phobicity of the substituted residue (Tadaki and Niyogi,and Leu69 of EGFR, has a shape roughly complementary
to that of the Ile side chain (Figure 3C). Mutations of 1993). This is in good agreement with the observation
that the aromatic side chains of Phe357 (EGFR) andMet21 and Leu26 of EGF also reduced the receptor
binding activity significantly (Campion et al., 1990). Fur- Tyr13 (EGF) are stacked upon each other (Figure 3D).
The Asp355 side chain of EGFR makes a salt bridgethermore, several hydrogen bonds are involved in the
ligand•receptor interactions. Residues 16–18 of EGFR with the Arg41 side chain of EGF (Figure 3D). Consis-
tently, the previous mutagenesis and biochemical stud-and residues 31–33 of EGF form a short parallel  sheet
in the present structure (Figure 3C). In addition, the ies showed that the Arg41 guanidium group of EGF is
a critical determinant for the receptor binding (Engler etGln16 side chain of EGFR hydrogen bonds with the
Asn32 side chain of EGF (Figure 3B). In this context, al., 1992). Furthermore, the long aliphatic portion of the
Arg41 (EGF) side chain provides van der Waals contactsthe replacement of Asn32 by Asp significantly reduced
Crystal Structure of EGF:EGF Receptor Complex
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Table 1. Crystallographic Data and Refinement Statistics
Diffraction Data Statistics
Crystal Native Se-Met
Remote Remote
Peak Edge (High Energy) (Low Energy)
Wavelength (A˚) 1.0000 0.9795 0.9798 0.9733 0.9839
Resolution (A˚) 50–3.3 50–3.5 50–4.0 50–4.0 50–4.0
Unique reflections 46,667 39,892 26,968 26,796 26,941
Total reflections 320,883 288,837 210,007 199,751 198,119
Rsym (%)a 7.8 (35.8)b 8.9 (38.4)b 7.2 (25.7)b 6.4 (22.0)b 5.7 (26.1)b
Completeness (%) 98.2 (92.6)b 98.5 (98.5)b 98.5 (97.0)b 98.3 (95.3)b 98.4 (95.9)b
I/(I) 21.5 (2.9)b 17.3 (2.1)b 21.7 (3.2)b 22.2 (3.6)b 20.5 (2.9)b
MAD Phasing
Se atoms found 13 (total 20)
Phasing powerc
Centric 0.73 0.78 0.33
Acentric (isomorphous) 1.09 1.18 0.45
Rcullisd
Centric 0.81 0.78 0.93
Acentric
Isomorphous 0.82 0.79 0.95
Anomalous 0.85 0.88 0.89 0.99
Figure of merit (after DM) 0.525 (0.856)
Refinement Statistics
Resolution 10.0–3.3 Rmsd from ideality
No. of reflections 44,854 Bond length (A˚) 0.006
No. of protein atoms 8,767 Bond angles () 1.39
No. of waters 79 Dihedrals () 25.1
R factor/Rfree (%)e 25.5/32.6 Improper () 0.781
R factor/Rfree (without waters) 26.4/33.2 Average B factor (A˚2) 82.5
a Rsym  h i|Ihi  Ih	|h i|Ihi|, where h are unique reflection indices, and i indicates symmetry equivalent indices.
b Numbers in parentheses correspond to the values in the highest resolution shell.
c Phasing power is frms/Erms, where frms  [(fH2)/n]1/2 and Erms  [ (FPH  |FP 
 FH|)2/n]1/2.
d Rcullis  |FH  (FPH  FP)/|FPH  FP|.
e R factor  |Fo  Fo|/Fo for reflections of the work set, and Rfree  |Fo  Fo|/Fo for reflections of the test set (5% of total reflections).
with the Tyr13 (EGF) and Phe357 (EGFR) side chains. similar interactions with sites 2 and 3 of EGFR. These
putative interactions are consistent with the NMR studyPart of site 2 is a loop consisting of residues 353–362
(Figure 3D), which corresponds well with the epitope of TGF- in the presence of EGFR, in which Phe15 and
Leu48 contribute to the receptor binding (McInnes et(residues 351–364) to the ligand-competitive mono-
clonal antibody LA22 (Wu et al., 1989). al., 2000). On the other hand, to allow the interactions
between the B loop of TGF- and site 1 in EGFR, aIn site 3, the side chains of Leu382, Phe412, and Ile438
(EGFR) are involved in hydrophobic interactions with conformational change of the TGF- B loop (or a shift
of domain I closer to domain III) should occur upon TGF-that of Leu47 (EGF) (Figure 3E). The Gln384 side chain
of EGFR hydrogen bonds with the main chain carbonyl -EGFR binding. Among the EGF residues that were
found to interact with EGFR in the present structure,and amide groups of Gln43 and Arg45, respectively, of
EGF. In mouse EGF, a lysine residue replacing Arg45 Met21, Leu26, and Asn32 are replaced by residues with
different properties in TGF-. It would be interesting towas crosslinked to Lys465 near site 3 in domain III (Sum-
merfield et al., 1996). The distance between the C compare details of the ligand•EGFR interaction between
EGF (this study) and TGF- (Garrett et al., 2002 [thisatoms of these residues in the present structure is 14 A˚
and is therefore consistent with the crosslinking study. issue of Cell]). In the case of neuregulin, which is a
specific ligand to ErbB-3 and ErbB-4, the N-terminal fiveThus, the present complex structure revealed the EGFR
residues that interact with the previously identified re- residues were shown to be essential for the binding to
ErbB-4 in a study of EGF/neuregulin chimeric proteinsceptor binding residues of EGF.
TGF- is a member of the EGF family of growth fac- (Barbacci et al., 1995). In contrast, the N-terminal region
of EGF is not involved in the present EGF•EGFR interac-tors. The TGF- molecule (Harvey et al., 1991) can fit
into the cleft of EGFR in place of the EGF molecule in tion, indicating that the ligand•receptor interaction is not
strictly conserved among the EGF and EGFR families.the present complex structure. However, the B loop of
TGF- would not contact site 1 of the receptor because Two crosslinking studies separately showed that the
N terminus of EGF was crosslinked to Tyr101 and Lys336of the difference in the B loop conformations between
TGF- and EGF. As Phe15 and Leu48 of TGF- corre- of EGFR (Wu et al., 1990; Woltjer et al., 1992). Actually,
no interaction was observed between EGFR and thespond to Tyr13 and Leu47 of EGF, TGF- may have
Cell
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Figure 3. Interactions between EGF and EGFR
EGF and the EGFR domains are colored in the same manner as in Figure 1, except for (B).
(A) Mapping the interaction sites onto ribbon representations of EGFR and EGF. Three binding sites in the interface are outlined.
(B) EGF structure. The A, B, and C loops are colored blue, green, and red, respectively. The other regions are pale green.
(C) Stereo view of the interface at site 1. Only the side chains of interacting residues are shown. Dotted lines represent hydrogen bonds.
(D) Stereo view of the interface at site 2.
(E) Stereo view of the interface at site 3.
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EGF N-terminal four residues, which are disordered in with their receptors (de Vos et al., 1992; Syed et al.,
1998). On the other hand, NGF and its receptor form athe present structure. However, the estimated distances
from Tyr101 and Lys336 of EGFR to the C atom of Glu5 2:2 complex solely through ligand•ligand interactions
(Wiesmann et al., 1999) (the “ligand dimerization” mech-of EGF are 16 and 39 A˚, respectively, suggesting that
the N terminus of EGF is capable of crosslinking to anism). GCSF forms a 2:2 ligand•receptor complex in a
different manner: each of the two ligands binds biva-Tyr101 but not to Lys336. Therefore, it is possible that
the stable, dimeric EGF•EGFR complexes determined lently with the two receptors, without any direct ligand•
ligand or receptor•receptor contact (Aritomi et al., 1999)here could be formed via some intermediate state(s), in
which EGF might bind to EGFR in different mode(s). (the “ligand-mediated” mechanism). In the heparin-sta-
bilized dimerization of the 1:1 FGF•FGFR complex, each
ligand bivalently binds to the two receptors, but not toReceptor•Receptor Interactions
the other ligand, while the two receptors interact directlyThe 2:2 EGF•EGFR complex (Figure 1) is the noncrys-
with each other (Plotnikov et al., 1999, 2000; Stauber ettallographic dimer of the 1:1 complexes A and B (the
al., 2000; Schlessinger et al., 2000). In another structure,“A•B” dimer). In addition, the 2:2 complexes make two
the 1:1 FGF•FGFR complex is dimerized primarily by thetypes of crystallographic contacts, primarily between
interaction of the two ligands to one heparin moleculetwo A molecules and between two B molecules of EGFR
(Pellegrini et al., 2000).(Figures 2C and 2D). These “A•A” and “B•B” contacts
In contrast, the present 2:2 EGF•EGFR complex struc-involve the flat, hydrophilic surfaces of EGFR, and the
ture demonstrates a new “receptor-mediated” mecha-total surface areas buried in these interfaces are 968 A˚2
nism; the two receptors bind each other directly, andand 392 A˚2, respectively (Figure 2C). In contrast, the
each of the two ligands binds only one receptor, withnoncrystallographic A•B interaction is much more inten-
no contact with the other receptor or ligand. In thissive and complicated, and the total surface area buried
unique mechanism of EGFR dimerization, each of thein this interface is about 1270 A˚2. Therefore, the A•B
two Cys-rich domains (domain II) extends the dimeriza-dimerization mechanism of EGF•EGFR is the most likely
tion arm to hold the body of the other. Therefore, thisto be physiological. Moreover, the TGF-•EGFR com-
“protruding arm” architecture, as well as the receptor-plex exhibits two possible modes of dimerization (Gar-
mediated nature, characterizes the EGFR dimerization.rett et al., 2002 [this issue of Cell]): one is the same as
Furthermore, the C-shaped arrangement of the threethe A•B interaction of the EGF•EGFR complex, and the
domains, I, II, and III, places the receptor-dimerizationother is completely different from the A•A and B•B con-
site away from the EGF binding sites, on the oppositetacts, reflecting the difference in the crystal form.
side of the receptor (Figure 1A).The receptor dimerization occurs mostly through in-
teractions between each domain II. A 20 residue region
(“dimerization arm”), forming a -hairpin in the middle, Comparison with the Unliganded
IGF-1R Structureprotrudes from the domain II globule of each receptor,
and the seven residues at the tip of the “arm” serve as The crystal structure of an IGF-1R fragment comprising
the first three domains (L1, Cys-rich, and L2) has beenits “hand” that interacts with the domain II globule of
the other receptor (Figures 4A and 4B). In the EGFR determined (Garrett et al., 1998). This IGF-1R fragment
is unable to bind the ligand, probably because it lacksdimer interface, Tyr246, Pro248, and Tyr251 in molecule
A provide hydrophobic interactions with Phe230*, the other ligand binding region (Garrett et al., 1998). The
present overall structure of the EGF•EGFR complex wasPhe263*, Ala265*, Tyr275*, and Arg285* of molecule B
(the asterisks indicate molecule B) (Figures 4C and 4D). compared with that of the unliganded IGR-1R. The struc-
tures of domains I, II, and III of EGFR are individuallyThese hydrophobic interactions are accompanied by
four hydrogen bonds between the side chains of Tyr251 similar to those of the first three domains of IGF-1R, as
described above. Furthermore, the arrangement be-and Arg285*, between the side chain of Gln252 and the
main chain amide group of Ala286*, and between the tween domains I and II of EGFR is quite similar to that
between the corresponding domains of IGF-1R (Figureside chain of Tyr246 and the main chain carbonyl group
of Cys283*. All of these receptor•receptor interactions 5). In contrast, there is a significant difference in the
arrangement of the third domain (III/L2) relative to theare symmetrically observed between molecules A and B
of EGFR. Phe230 and Tyr246 are conserved, and Tyr251, second domain (II/Cys-rich) (Figure 5). The conformation
around Lys311 in the hinge region between domains IIPhe263, and Ala265 are either conserved or replaced
by homologous amino acids, among the mammalian, and III of EGFR (Figure 6A) is different from that of the
corresponding residue in IGR-1R, and domain II con-chicken, and fly EGFR families. Therefore, the dimeriza-
tion arms are probably involved in the homo- and hetero- tacts domain III in the EGF bound EGFR structure. While
this interface has higher B factors, domains II and IIIdimerizations between the EGFR family members. In
addition to the conserved interactions between each could form hydrogen bonds between the side chain of
Asn274 and the main chain carbonyl groups of Arg403domain II, the present EGF•EGFR complex structure
shows a hydrogen bond between Thr249 from the hand and Gly404, and between the side chains of Glu293 and
Arg405 (Figure 5C). In contrast, in the unliganded IGF-1Rof the domain II dimerization arm of one receptor and
Asn86 of domain I of the other (Figure 4). structure, the corresponding residues are not involved in
interdomain interactions, while the side chain and theThe architecture of the 2:2 EGF•EGFR complex de-
scribed above clearly differs from those of other protein main chain amide and carbonyl groups of Lys300 (the
putative hinge residue corresponding to Lys311 ofligand•receptor complexes reported thus far. Human
growth hormone and erythropoietin form 1:2 complexes EGFR) hydrogen bond with the main chain carbonyl
Cell
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Figure 4. Interactions between Each Recep-
tor in the Dimer Interface
(A) The binding region in the interface is out-
lined. Only the side chains of interacting resi-
dues are shown. EGF and the EGFR domains
are colored in the same manner as in Fig-
ure 1.
(B) Stereo view of an annealed omit map. Res-
idues 240–260 and the residues within 3.5 A˚
from them of one EGRF molecule (orange)
were omitted.
(C) Stereo view of the interface from the view
shown by the arrow in (A); the view is directed
from the front side of domain I toward Y251
of the other receptor. Dotted lines represent
hydrogen bonds.
(D) Stereo view of the interface from the view
shown by the arrow in (A); the view is directed
from the back side of domain I toward Y251
of the other receptor.
group of Gln321, the side chain of Thr324, and the main tated, and their effects on the full-length EGFR activation
chain amide group of Thr324, respectively (Garrett et were examined. First, we assayed the EGF-dependent
al., 1998). phosphorylation of the extracellular signal-regulated
protein kinases (ERKs) as a probe for the downstream
signaling pathway of EGFR expressed in CHO cells (Fig-EGFR Mutagenesis
ure 6A). In the hydrophobic receptor-dimerization inter-The crystal structure of the EGF•EGFR complex re-
face, Tyr251 of one receptor hydrogen bonds withvealed the dimerization interface between the two re-
ceptors. Thus, the interface residues of EGFR were mu- Arg285 and hydrophobically interacts with Phe263 of
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Figure 5. Comparison of the Overall Folds of the Liganded EGFR with the Unliganded IGF-1R and the Interface between Domains II and III
in the Liganded EGFR Monomer in the Dimer
(A) Ribbon diagram of the 1:1 EGF•EGFR complex.
(B) Ribbon diagram of unliganded IGF-1R. The view for the L1 and Cys-rich domains is the same as that for domains I and II in (A).
(C) Stereo view of the interface between domains II and III in the liganded EGFR monomer.
the other receptor (Figures 4C and 4D). The replacement ceptor dimerization interface found in the present crystal
structure was verified by the mutagenesis. Intriguingly,of Arg285 by Tyr (R285Y) had a negligible effect, but
that by Ser (R285S) reduced the bioactivity (Figure 6A). the two dimerization-interface mutants exhibited much
lower affinities for EGF in the [125I]EGF binding assayFurthermore, the combination of the R285S mutation
with either Y251A or F263A caused a nearly complete (Figure 6D), suggesting that the high-affinity EGF bind-
ing is related to the EGFR dimerization.loss of the activity, while the individual Ala mutations of
Tyr251 and Phe263 exhibited negligible effects. The cell On the other hand, the intramolecular interaction be-
tween domains II and III of EGFR was also tested bysurface expression levels of both EGFR mutants that
failed to activate the ERK were confirmed to be nearly the mutagenesis. In this domain•domain interface,
Glu293 of domain II and Arg405 of domain III form a saltthe same as that of the wild-type EGFR, by both biotiny-
lation (Figure 6B) and FACS analyses (data not shown). bridge with each other (Figure 5C). Correspondingly,
the replacement of Arg405 by Glu abolished the EGF-These nonsignaling forms were also incapable of EGFR
autophosphorylation (Figure 6C). Consequently, the re- dependent ERK phosphorylation, autophosphorylation,
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Figure 6. EGF-Induced EGFR Activation in
CHO Cells Expressing Mutant EGFRs
The wild-type and mutant EGFRs were tran-
siently expressed in CHO cells.
(A) EGF-induced ERK phosphorylation. Se-
rum-starved transfectants were treated with
EGF. Cell lysates were examined by immu-
noblot analyses using an anti-phospho-ERKs
antibody (-p-ERKs) and an anti-EGFR anti-
body (-EGFR). Membranes were stripped
and reprobed with an anti-ERKs antibody to
control for protein loading (-ERKs).
(B) Cell surface expression of mutant EGFR.
Biotinylated cell lysates were examined by
an immunoblot analysis using an anti-EGFR
antibody (-EGFR).
(C) EGF-induced autophosphorylation of
EGFR. Stimulated cell lysates were examined
by an immunoblot analysis using an anti-
phospho-Tyr antibody (-pY).
(D) Binding of 125I-labeled human EGF (2 nM)
to the cells expressing mutant EGFR. The SD
(n  3) is shown as an error bar.
Lec8 transfectants were maintained using Dulbecco’s modifiedand high-affinity EGF binding (Figure 6). Therefore, the
Eagle’s medium/Ham’s F-12 medium (1:1) (DMEM/F12) supple-domain•domain interaction is important for the receptor
mented with 10% calf serum, 100 units/ml penicillin, 100 g/mlactivation.
streptomycin, and 20 mg/l proline. For large-scale protein produc-
tion, the Lec8 transfectant was grown in the medium containing 1%
Domain IV calf serum. After the medium was harvested, 0.4 mM EDTA and
0.4 mM phenylmethylsulfonylfluoride were added. The medium wasThe 2:2 complexes EGF•EGFR (this study) and TGF-•
fractionated by ammonium sulfate (AS) at 4C to remove the serumEGFR (Garrett et al., 2002 [this issue of Cell]) have re-
globulin (280 g of AS to 1000 ml of the medium) and to precipitatevealed a novel mechanism of receptor dimerization. How
EGFR (an additional 280 g of AS). The pellets were dissolved in and
does this receptor-mediated dimerization of EGFR prop- dialyzed against 20 mM phosphate buffer (pH 7.1) (buffer A) and
erly orient the two cytoplasmic tyrosine kinase domains were stored at 80C until the next step. All further steps were
to activate the intrinsic receptor tyrosine kinase activity? performed at 4C. Next, the sample was loaded on tandemly con-
nected, buffer A-equilibrated columns of DEAE-Toyopearl 650, CM-For the present EGF complex with the four domain extra-
Toyopearl 650 (Tosoh), and Affi-Gel Blue gel (Bio-Rad). The proteincellular region of EGFR, domains I, II, and III are well
was eluted from the disconnected Affi-Gel Blue column with a gradi-ordered, but domain IV is much less ordered. Corre-
ent of 20 to 600 mM NaCl. The elutant was applied to an anti-FLAG
spondingly, the two sets of EGF and domains I, II, and M2 affinity gel column equilibrated with buffer A with an additional
III are all firmly fixed, while domain IV does not tightly 150 mM NaCl. Bound proteins were recovered with 100 mM glycine-
HCl buffer (pH 3.5) and were neutralized immediately. The elutantinteract with the other domains. It is important to deter-
was dialyzed against 20 mM Tris-HCl buffer (pH 8.0) containingmine the domain IV orientation in the EGF•EGFR dimer,
20 mM NaCl (buffer B) and was loaded onto a Mono-Q columnon which the distance between the cellular protein ki-
(Amersham Biosciences) equilibrated with buffer B. EGFR was
nase domains depends. eluted with a gradient of 20 to 200 mM NaCl and was deglycosylated
enzymatically, as follows. The concentration of EGFR was deter-
Experimental Procedures mined using the extinction coefficient at 280 nm (0.65). EGFR
(2 mg/ml) was incubated with 0.4 unit/ml endoglycosidase D and
Preparations of Native and 1 unit/ml endoglycosidase H in 100 mM sodium acetate buffer (pH
Selenomethione-Substituted Proteins 5.3) for 50 hr at 37C under an argon atmosphere. Then, the deglyco-
The expression plasmid pcDNA-sEGFR was constructed as follows. sylated EGFR was purified on the Mono-Q column in the same way
A forward oligonucleotide primer was used in a standard PCR proto- as for the first Mono-Q chromatography, as described above.
col with a reverse oligonucleotide primer that encodes a thrombin For the production of selenomethionyl EGFR, DMEM/F12 con-
cleavage site, a FLAG epitope, and a stop codon. The plasmid taining 50 mg/l fresh selenomethionine (substituted for methionine),
encoding the full-length human EGFR was used as the template 1% dialyzed calf serum, 100 units/ml penicillin, 100 g/ml strepto-
(Sato et al., 2000). The amplified DNA was cloned into the pcDNA3.1/ mycin, and 40 mg/l proline (SeMet medium) was prepared. Lec8
Zeo(
) vector (Invitrogen) to create the plasmid pcDNA-sEGFR transfectants were grown in the same way as for the production of
(amino acid residues 1–619). Lec8 cells (CRL-1737, American Tissue native EGFR, and then the medium was changed to SeMet medium.
Culture Collection) were transfected with the plasmid by the Lipofec- After a 12–24 hr preincubation, the cells were incubated in fresh
tamine method, according to the manufacturer’s recommendations SeMet medium for 3 days, and then the medium was harvested.
(GIBCO-BRL). Stable transfectants were obtained as previously de- Selenomethionyl EGFR was purified in the same way as for the
native EGFR, as described above.scribed (Kim et al., 2002).
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Crystallization Mutagenesis Studies
The site-directed mutagenesis was performed with the Quick-The EGF•EGFR complex solution for crystallization was prepared
as follows. The purified EGFR solution was concentrated to 10 Change site-directed mutagenesis kit, according to the manufactur-
er’s recommendations (Stratagene). The mutation in the EGFR se-mg/ml, as determined using the extinction coefficient at 280 nm
(0.79). An eqimolar amount of recombinant human EGF (Pepro-Tech) quence was confirmed by DNA sequence analysis. CHO cells were
maintained in Minimum Essential Medium Alpha, supplemented withwas purified by reversed phase HPLC, freeze-dried, and dissolved
in the EGFR solution to form the complex. The crystals were grown 10% calf serum, and were transfected with an expression vector
carrying the wild-type or mutant receptor by the FuGENE6 method,at 20C by the hanging-drop vapor diffusion method over a period
of 3 weeks, starting from 3 l of the complex solution and 3 l of according to the manufacturer’s recommendations (Roche). Then,
the transiently transfected CHO cells were maintained for 24 hr,reservoir solution containing 15% PEG4000, 1% PEG6000, 75 mM
Tris-HCl (pH 8.4), 75 mM sodium acetate, and 200 mM sodium unless otherwise described, and were used for further analyses with
and without a 24 hr starvation, followed by stimulation with humanchloride. The macroseeding method was used to reproducibly grow
the crystal to 1  0.2  0.2 mm or more. EGF for 5 min. The EGFR expression and the downstream ERKs
activation in the transiently transfected CHO cells were determined
(Kim et al., 2002), and immunoblot analyses were performed using
Diffraction Data Collection an anti-EGFR polyclonal antibody (Upstate Biotechnology), an anti-
The crystals were cautiously transferred by many steps from harvest phospho-p44/42 MAP kinase E10 monoclonal antibody, and an anti-
buffer (1.2-fold concentration of reservoir buffer) to harvest buffer MAP kinase polyclonal antibody (Cell Signaling Technology). Then,
including 16% trehalose and 11% PEG400 as cryoprotectants. Be- for the wild-type and ERK-activation-deficient mutants, the expres-
fore freezing with liquefied nitrogen, the crystals were slowly cooled sion of EGFR on the surface of the transiently transfected CHO cells
to 4C, and then were placed on ice for 2 days. This treatment was confirmed by the following two methods. First, the cell-surface
decreased the mosaicity of the crystals. X-ray diffraction data were proteins were biotinylated, and the biotinylated EGFR was detected
collected on beamline BL41XU at SPring-8 (Harima, Japan). The as described (Muthuswamy et al., 1999). Second, the cell surface
native crystals of the EGF•EGFR complex belong to the space group EGFR of the transient transfectant was labeled with the anti-EGFR
P3121, with unit cell dimensions a b 220.2 A˚ and c 113.1 A˚. The 528 monoclonal antibody (Santa Cruz) and then was analyzed with
selenomethionine-labeled crystals also belong to the same space a FACS Vantage SE system (Becton Dickinson) according to the
group, with unit cell dimensions a b 221.2 A˚ and c 114.2 A˚. The manufacturer’s instructions. For the detection of EGF-induced auto-
data sets of the selenomethionine-labeled crystals were collected at phosphorylation, the transiently transfected cells were maintained
wavelengths of 0.9795 A˚ (peak), 0.9798 A˚ (edge), 0.9839 A˚ (low- for 12 hr and then were starved for 3 hr in serum-free medium. EGFR
energy remote), and 0.9733 A˚ (high-energy remote) for the MAD autophoshorylation was determined as previously described (Sato
phasing procedure. The resulting data sets were processed and et al., 2000). For the EGF binding assay, the transiently transfected
reduced using the program suite HKL2000 (Otwinowski and Minor, cells, in a 24-well plate coated with fibronectin, were maintained for
1997). 24 hr and then were starved for 24 hr in serum-free medium. The
cells were incubated with 2 nM 125I-labeled EGF in phosphate-buf-
fered saline (PBS) containing 1 mg/ml BSA for 1 hr. The free 125I-
Structure Determination and Refinement EGF was removed by washing three times with ice-cold PBS con-
The data set of the selenomethionine-labeled crystal at the peak taining 1 mg/ml BSA. The cells were lysed in 0.5 ml of 0.5 M NaOH,
wavelength was used to locate the selenium atoms, using the pro- and the radioactivity was measured by a  counter.
gram SnB (Weeks and Miller, 1999). The 13 peaks were picked out
of the 20 atoms expected in the asymmetric unit (Figure 2A). The Acknowledgments
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